重复经颅磁刺激治疗难治性重性抑郁症退伍军人患者:一项随机对照试验的研究方案
该研究为美国退伍军人事务部合作研究项目(CSP No. 556)资助的多中心、随机、双盲、意向性治疗、两臂、优效性平行设计试验,计划在9个退伍军人医疗中心纳入360例难治性重性抑郁症退伍军人,随机分配至左侧前额叶rTMS治疗组或假rTMS对照组(每组180例),最多30次治疗,主要结局为缓解率(HRSD24≤10)。
要点
- 计划纳入360例符合DSM-IV重性抑郁症且至少两种药物治疗失败的退伍军人。
- 随机分为左侧前额叶rTMS组或假rTMS组,每组180例,最多30次治疗。
- 不排除共病PTSD或物质滥用史者,试验期间维持稳定抗抑郁药物治疗。
核心结论
- 该研究方案描述了一项在退伍军人难治性重性抑郁症患者中评估左侧前额叶rTMS疗效的多中心随机双盲优效性试验。
研究设计与样本
- 随机、双盲、意向性治疗、两臂、优效性平行设计的多中心研究,由美国退伍军人事务部合作研究项目(CSP No. 556)资助。
- 计划在9个退伍军人医疗中心招募360例诊断为难治性重性抑郁症的退伍军人,随机分为左侧前额叶rTMS组或假rTMS对照组,每组180例,最多30次治疗。
主要发现
- 所有参与者须符合DSM-IV重性抑郁症标准且至少两种既往药物治疗失败。
- 不排除有创伤后应激障碍或物质滥用史的退伍军人,并将获取这些疾病的详细病史。
- 试验期间维持参与者使用稳定的抗抑郁药物。
- 评估包括认知、心理和功能参数在内的多种潜在治疗反应预测因素。
关键数值与推荐
- 主要依赖测量指标为缓解率,定义为汉密尔顿抑郁评定量表24项版(HRSD24)评分≤10。
- 在急性治疗阶段结束时比较rTMS组与假rTMS组以检验主要假设。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evaluation of repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depression (TRMD) in Veterans offers unique clinical trial challenges. Here we describe a randomized, double-blinded, intent-to-treat, two-arm, superiority parallel design, a multicenter study funded by the Cooperative Studies Program (CSP No. 556) of the US Department of Veterans Affairs. METHODS: We recruited medical providers with clinical expertise in treating TRMD at nine Veterans Affairs (VA) medical centers as the trial local investigators. We plan to enroll 360 Veterans diagnosed with TRMD at the nine VA medical centers over a 3-year period. We will randomize participants into a double-blinded clinical trial to left prefrontal rTMS treatment or to sham (control) rTMS treatment (180 participants each group) for up to 30 treatment sessions. All participants will meet Diagnostic and statistical manual of mental disorders, 4 th edition (DSM-IV) criteria for major depression and will have failed at least two prior pharmacological interventions. In contrast with other rTMS clinical trials, we will not exclude Veterans with posttraumatic stress disorder (PTSD) or history of substance abuse and we will obtain detailed history regarding these disorders. Furthermore, we will maintain participants on stable anti-depressant medication throughout the trial. We will evaluate all participants on a wide variety of potential predictors of treatment response including cognitive, psychological and functional parameters. DISCUSSION: The primary dependent measure will be remission rate (Hamilton Rating Scale for Depression (HRSD24) ≤ 10), and secondary analyses will be conducted on other indices. Comparisons between the rTMS and the sham groups will be made at the end of the acute treatment phase to test the primary hypothesis. The unique challenges to performing such a large technically challenging clinical trial with Veterans and potential avenues for improvement of the design in future trials will be described. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01191333 . Registered on 26 August 2010. This report is based on the protocol version 4.6 amended in February 2016. All items from the World Health Organization Trial Registration Data Set are listed in Appendix A.
引用
- Mi Z, Biswas K, Fairchild JK, et al. Repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depression (TRMD) Veteran patients: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28865495. doi:10.1186/s13063-017-2125-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。